Up To 50 SAR OFF Your First Order Use Code : APP50 | Get Free Delivery With No Minimum Order

Frequently bought together
DAONIL M TAB 5
- Sku : I-012271
Key features
DAONIL M TAB 5 is a 5 mg tablet containing the active ingredient glibenclamide. It stimulates insulin secretion by closing pancreatic beta-cell ATP-sensitive K+ (SUR1) channels, leading to membrane depolarization, Ca2+ influx and insulin release. It is indicated for the treatment of type 2 diabetes mellitus in adults when diet and exercise alone are insufficient. Available by prescription in packs of 30 tablets.- Brand: DAONIL
- Active Ingredient: GLIBENCLAMIDE 5mg
- Strength: 5mg
- Dosage Form: Tablet
- Pack Size: 30 Tablets
- Route: Oral use
- Prescription Status: Prescription
- Therapeutic Class: Antidiabetic
- Pharmacological Group: Sulfonylureas
- Drug Class: Second-generation Sulfonylurea Antidiabetic
- Manufacturer: SANOFI WINTHROP INDUSTRIE
- Country of Origin: France
- SFDA Registration No.: 2111246317
- Shelf Life: 24 months
- Storage: store below 25°c
- Diabetes Type: Type 2
Frequently bought together
Indications
Approved Uses
Type 2 diabetes mellitus in adults when diet and exercise alone are insufficient
Dosage & Administration
Dosing by Condition
Type 2 diabetes mellitus (adjunct to diet/exercise): Initial 2.5-5 mg once daily with breakfast/first main meal; titrate by ~2.5 mg at ~weekly intervals based on glucose; usual maintenance ~5-15 mg/day; doses >10 mg/day may be divided; maximum 20 mg/day.
Initial Dose
2.5mg to 5mg once daily with breakfast or the first main meal.
Maintenance Dose
5-15 mg/day as a single morning dose or in divided doses
Maximum Dose
20mg per day.
Children's Dosage
Not approved for children.
Dose Adjustment Notes
Individualize and titrate based on glucose; start low and titrate gradually (e.g., 2.5 mg increments at ~weekly intervals); consider dividing doses when >10 mg/day; use lower starting doses and cautious titration in elderly/debilitated/malnourished and in renal/hepatic impairment due to hypoglycemia risk (avoid/use extreme caution in severe impairment per labeling/guidelines).
How to Take
Swallow whole with water; take with breakfast or the first main meal of the day; maintain consistent meal timing
Side Effects
Common Side Effects
Hypoglycemia; weight gain; gastrointestinal upset (nausea, vomiting, diarrhea, abdominal/epigastric discomfort/heartburn, feeling of fullness)
Safety & Warnings
Contraindications
Hypersensitivity to glibenclamide/sulfonylureas; type 1 diabetes; diabetic ketoacidosis; diabetic coma/pre-coma; severe renal impairment; severe hepatic impairment; pregnancy (generally avoid-insulin preferred); concomitant bosentan (contraindicated).
Age Restriction
Not recommended/Not indicated in children and adolescents (<18 years); use only under specialist direction if ever considered.
Drug Interactions
Food Interaction
Take with food (with breakfast or the first main meal).
Special Populations
Children
Not approved for children.
Elderly
Start at 2.5 mg/day; titrate slowly with close blood glucose monitoring; increased risk of prolonged hypoglycemia; avoid if possible in patients over 65 with renal impairment
Storage & Patient Advice
Overdose
Overdose causes potentially prolonged severe hypoglycemia (confusion, seizures, coma); treat with rapid glucose (oral if conscious) and IV dextrose if severe/unconscious, with prolonged monitoring (often 24-48+ hours) and repeat dextrose as needed.
Pharmacology
Mechanism of Action
Stimulates insulin secretion by closing pancreatic beta-cell ATP-sensitive K+ channels (SUR1), causing depolarization, Ca2+ influx, and insulin release.
Onset of Action
Insulin response begins within ~15-60 minutes; clinical glucose-lowering onset is about ~1 hour.
Duration of Effect
Up to ~24 hours (commonly ~16-24 hours)
Half-Life
Approximately 10 hours (variable; commonly reported range ~5-16 hours).
Bioavailability
Rapidly and nearly completely absorbed (high oral bioavailability).
Metabolism
Extensively hepatic metabolism, primarily via CYP2C9 (minor CYP3A4), to hydroxy metabolites (4-trans-hydroxy and 3-cis-hydroxy) that have reduced/weak hypoglycemic activity; metabolites are eliminated in urine and bile.
Protein Binding
>99% protein bound (mainly to albumin).
Product Information
Available Dosage Forms
Tablet (oral)
Composition per Dose
Each tablet: 5 mg glibenclamide
Generic Availability
Yes
OTC Alternatives
No OTC alternative
Diabetes Type
Type 2
Legal Disclaimer - Al Mujtama Pharmacy
The product information provided is derived from verified pharmaceutical references and is intended for general health education only. It is not a substitute for professional medical advice, diagnosis, or treatment.
Al Mujtama Pharmacy assumes no legal or medical liability for:
- Any therapeutic decision made based on the information displayed without consulting a licensed physician or pharmacist
- Any discrepancy between the information provided and the product's package insert or SFDA guidelines
- Any misuse of medication resulting from personal interpretation of the content displayed
Important notice: Drug formulations and instructions may vary between production batches. Always rely on the leaflet included inside the product packaging you have, and consult your pharmacist or physician before starting, adjusting, or discontinuing any medication.
By using this content, you acknowledge that you have read this disclaimer and agree that Al Mujtama Pharmacy bears no liability arising from reliance on this information as a substitute for direct medical consultation.
Your health is a trust - always consult your doctor first.
-1744229570.gif)













